Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study
| Autor: | Marleen M. M. Mitschek, Richard Frey, Gernot Fugger, Alexander Kautzky, Lucie Bartova, Joseph Zohar, Daniel Souery, Stuart Montgomery, Chiara Fabbri, Markus Dold, Siegfried Kasper, Alessandro Serretti, Julien Mendlewicz |
|---|---|
| Přispěvatelé: | Dold M., Bartova L., Fugger G., Mitschek M.M.M., Kautzky A., Frey R., Montgomery S., Zohar J., Mendlewicz J., Souery D., Fabbri C., Serretti A., Kasper S. |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.drug_class Antidepressant Major depressive disorder Treatment response Treatment resistant depression Benzodiazepines 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Pharmacology (medical) Augmentation/combination treatment Biological Psychiatry Depression (differential diagnoses) Aged Retrospective Studies Pharmacology Depressive Disorder Major Benzodiazepine business.industry Lorazepam Middle Aged medicine.disease Antidepressive Agents Clonazepam 030227 psychiatry Europe Psychiatry and Mental health Cross-Sectional Studies Treatment Outcome Neurology Alprazolam Drug Therapy Combination Female Neurology (clinical) business Treatment-resistant depression 030217 neurology & neurosurgery medicine.drug |
| Popis: | Since many patients with major depressive disorder (MDD) do not satisfactorily respond to initial antidepressant monotherapy, add-on treatment strategies with other psychiatric compounds are often established. The present European multicenter cross-sectional study comprising 1410 MDD in- and outpatients investigated the prescription pattern of benzodiazepines as add-on treatment in the psychopharmacotherapy of MDD. Analyses of variance, chi-squared tests, and logistic regression analyses were conducted to examine differences in socio-demographic, clinical, and treatment characteristics between benzodiazepine users and non-users. The prescription rate for adjunctive benzodiazepine treatment amounted to 31.35%. The most often administered benzodiazepines were lorazepam (11.13%), clonazepam (6.74%), and alprazolam (6.60%). Benzodiazepine users exhibited more severe depressive symptoms expressed by a higher mean Montgomery and Åsberg Depression Rating Scale total score at study entry (26.92 ± 11.07 vs 23.55 ± 11.23, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|